The carbohydrate restriction of ketogenic diets further reduces glucose availability, potentially necessitating medication adjustments
Neuroscience Letters, 488(1), 7680
Acknowledgements The authors would like to thank Henrik Kim Nielsen, Jens Heisterberg, and Karen Hauda (Novo Nordisk A/S, Denmark), and Gina MacNeil (Novo Nordisk Inc, United States) for review of, and input to, the manuscript, as well as Tina stergaard, Sisse Lakner Schmidt, and Michala Cronberg (Novo Nordisk A/S, Denmark) for help with physical stability analyses
[40] reported that exendin-4 increased LXR-mediated ABCA1 expression through AMPK activation, improving cholesterol-induced toxicity in INS-1 cells
Standard dosage is 2-3g daily for fat loss and athletic performance
The peptide also suppresses glucagon secretion, reducing hepatic glucose production and helping keep stable blood glucose levels